GlobeNewsWire · SITC · November 6, 2026

Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026

Get the app for more

Explore stock news, insights and company research.